Link between chronic obstructive pulmonary disease and coronary artery disease: Implication for clinical practice

Respirology

Volumn 17, Issue 3, 2012, Pages 422-431

  Boschetto, Piera ^a   Beghé, Bianca ^b   Fabbri, Leonardo M ^b   Ceconi, Claudio ^c  

^a UNIVERSITY OF FERRARA   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITY HOSPITAL OF FERRARA   (Italy)

Author keywords

cardiovascular disease; chronic obstructive pulmonary disease; clinical epidemiology; emphysema; inflammation

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; IVABRADINE; NITRATE; STATIN;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL PRACTICE; COMORBIDITY; CORONARY ARTERY BYPASS GRAFT; CORONARY ARTERY DISEASE; DISEASE COURSE; DISEASE SEVERITY; DRUG DOSE TITRATION; EPIDEMIC; FATIGUE; FORCED EXPIRATORY VOLUME; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HOSPITALIZATION; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PREVALENCE; PRIMARY PREVENTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEXUAL DYSFUNCTION; SKELETAL MUSCLE; SPIROMETRY; TERTIARY HEALTH CARE; TRANSLUMINAL CORONARY ANGIOPLASTY;

COMORBIDITY; CORONARY ARTERY DISEASE; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MYOCARDIAL REVASCULARIZATION; PRACTICE GUIDELINES AS TOPIC; PREVALENCE; PROGNOSIS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; SEVERITY OF ILLNESS INDEX;

EID: 84859061063     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/j.1440-1843.2011.02118.x     Document Type: Review

References (77)

1. Global Initiative for Chronic Obstructive Lung Disease (GOLD). Global Strategy for the Diagnosis, Management and Prevention of COPD, 2010. [Accessed 20 Dec 2011.] Available from URL
2. Jensen HH, Godtfredsen NS, Lange P, et al,. Potential misclassification of causes of death from COPD. Eur. Respir. J. 2006; 28: 781-5.
3. Mathers CD, Loncar D,. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006; 3: e442.
4. Camilli AE, Robbins DR, Lebowitz MD,. Death certificate reporting of confirmed airways obstructive disease. Am. J. Epidemiol. 1991; 133: 795-800.
5. Jousilahti P, Vartiainen E, Tuomilehto J, et al,. Symptoms of chronic bronchitis and the risk of coronary disease. Lancet 1996; 348: 567-72.
6. Engstrom G, Wollmer P, Hedblad B, et al,. Occurrence and prognostic significance of ventricular arrhythmia is related to pulmonary function: a study from "men born in 1914," Malmo, Sweden. Circulation 2001; 103: 3086-91.
7. Hole DJ, Watt GC, Davey-Smith G, et al,. Impaired lung function and mortality risk in men and women: findings from the Renfrew and Paisley prospective population study. BMJ 1996; 313: 711-15, discussion 5-6.
8. Soriano JB, Visick GT, Muellerova H, et al,. Patterns of comorbidities in newly diagnosed COPD and asthma in primary care. Chest 2005; 128: 2099-107.
9. Curkendall SM, DeLuise C, Jones JK, et al,. Cardiovascular disease in patients with chronic obstructive pulmonary disease, Saskatchewan Canada cardiovascular disease in COPD patients. Ann. Epidemiol. 2006; 16: 63-70.
10. Sin DD, Man SF,. Why are patients with chronic obstructive pulmonary disease at increased risk of cardiovascular diseases? The potential role of systemic inflammation in chronic obstructive pulmonary disease. Circulation 2003; 107: 1514-19.
11. Feary JR, Rodrigues LC, Smith CJ, et al,. Prevalence of major comorbidities in subjects with COPD and incidence of myocardial infarction and stroke: a comprehensive analysis using data from primary care. Thorax 2010; 65: 956-62.
12. Agusti A, Calverley PM, Celli B, et al,. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir. Res. 2010; 11: 122.
13. Chapman KR, Mannino DM, Soriano JB, et al,. Epidemiology and costs of chronic obstructive pulmonary disease. Eur. Respir. J. 2006; 27: 188-207.
14. Hadi HA, Zubaid M, Al Mahmeed W, et al,. Prevalence and prognosis of chronic obstructive pulmonary disease among 8167 Middle Eastern patients with acute coronary syndrome. Clin. Cardiol. 2010; 33: 228-35.
15. Wakabayashi K, Gonzalez MA, Delhaye C, et al,. Impact of chronic obstructive pulmonary disease on acute-phase outcome of myocardial infarction. Am. J. Cardiol. 2010; 106: 305-9.
16. Hawkins NM, Huang Z, Pieper KS, et al,. Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur. J. Heart Fail. 2009; 11: 292-8.
17. Salisbury AC, Reid KJ, Spertus JA,. Impact of chronic obstructive pulmonary disease on post-myocardial infarction outcomes. Am. J. Cardiol. 2007; 99: 636-41.
18. Behar S, Panosh A, Reicher-Reiss H, et al,. Prevalence and prognosis of chronic obstructive pulmonary disease among 5,839 consecutive patients with acute myocardial infarction. SPRINT Study Group. Am. J. Med. 1992; 93: 637-41.
19. Bursi F, Vassallo R, Weston SA, et al,. Chronic obstructive pulmonary disease after myocardial infarction in the community. Am. Heart J. 2010; 160: 95-101.
20. Soriano JB, Rigo F, Guerrero D, et al,. High prevalence of undiagnosed airflow limitation in patients with cardiovascular disease. Chest 2010; 137: 333-40.
21. Rabe KF, Hurd S, Anzueto A, et al,. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am. J. Respir. Crit. Care Med. 2007; 176: 532-55.
22. El-Menyar A, Zubaid M, Rashed W, et al,. Comparison of men and women with acute coronary syndrome in six middle eastern countries. Am. J. Cardiol. 2009; 104: 1018-22.
23. Kjoller E, Kober L, Iversen K, et al,. Importance of chronic obstructive pulmonary disease for prognosis and diagnosis of congestive heart failure in patients with acute myocardial infarction. Eur. J. Heart Fail. 2004; 6: 71-7.
24. Mannino DM, Thorn D, Swensen A, et al,. Prevalence and outcomes of diabetes, hypertension and cardiovascular disease in COPD. Eur. Respir. J. 2008; 32: 962-9.
25. Sin DD, Man SF,. Systemic inflammation and mortality in chronic obstructive pulmonary disease. Can. J. Physiol. Pharmacol. 2007; 85: 141-7.
26. Donaldson GC, Hurst JR, Smith CJ, et al,. Increased risk of myocardial infarction and stroke following exacerbation of COPD. Chest 2010; 137: 1091-7.
27. Sin DD, Leung R, Gan WQ, et al,. Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: a pilot study. BMC Pulm. Med. 2007; 7: 13.
28. Barnes PJ,. Chronic obstructive pulmonary disease: effects beyond the lungs. PLoS Med. 2010; 7: e1000220. doi:10.1371/journal.pmed.1000220
29. Barnes PJ, Celli BR,. Systemic manifestations and comorbidities of COPD. Eur. Respir. J. 2009; 33: 1165-85.
30. Hurst JR, Wilkinson TM, Perera WR, et al,. Relationships among bacteria, upper airway, lower airway, and systemic inflammation in COPD. Chest 2005; 127: 1219-26.
31. De Martinis M, Franceschi C, Monti D, et al,. Inflamm-ageing and lifelong antigenic load as major determinants of ageing rate and longevity. FEBS Lett. 2005; 579: 2035-9.
32. De Martinis M, Franceschi C, Monti D, et al,. Inflammation markers predicting frailty and mortality in the elderly. Exp. Mol. Pathol. 2006; 80: 219-27.
33. Tsuji T, Aoshiba K, Nagai A,. Alveolar cell senescence in patients with pulmonary emphysema. Am. J. Respir. Crit. Care Med. 2006; 174: 886-93.
34. Topsakal R, Kalay N, Ozdogru I, et al,. Effects of chronic obstructive pulmonary disease on coronary atherosclerosis. Heart Vessels 2009; 24: 164-8.
35. Enriquez JR, Parikh SV, Selzer F, et al,. Increased adverse events after percutaneous coronary intervention in patients with COPD: insights from the national heart, lung, and blood institute dynamic registry. Chest 2011; 140: 604-10.
36. Wilt TJ, Rubins HB, Collins D, et al,. Correlates and consequences of diffuse atherosclerosis in men with coronary heart disease. Veterans Affairs High-Density Lipoprotein Intervention Trial Study Group. Arch. Intern. Med. 1996; 156: 1181-8.
37. Graham I, Atar D, Borch-Johnsen K, et al,. European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur. J. Cardiovasc. Prev. Rehabil. 2007; 14 (Suppl 2): S1-113.
38. Fox K, Garcia MA, Ardissino D, et al,. Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur. Heart J. 2006; 27: 1341-81.
39. Wijns W, Kolh P, Danchin N, et al,. Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS). Eur. Heart J. 2010; 31: 2501-55.
40. Yusuf S, Hawken S, Ounpuu S, et al,. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937-52.
41. Kotseva K, Wood D, De Backer G, et al,. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet 2009; 373: 929-40.
42. Reiner Z, Catapano AL, De Backer G, et al,. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur. Heart J. 2011; 32: 1769-818.
43. Reed RM, Iacono A, DeFilippis A, et al,. Statin therapy is associated with decreased pulmonary vascular pressures in severe COPD. COPD 2011; 8: 96-102.
44. Wright JL, Zhou S, Preobrazhenska O, et al,. Statin reverses smoke-induced pulmonary hypertension and prevents emphysema but not airway remodeling. Am. J. Respir. Crit. Care Med. 2011; 183: 50-58.
45. Antoniu SA,. Reducing mortality for chronic obstructive pulmonary disease: role of statins and angiotensin-converting enzyme inhibitors. Expert Rev. Pharmacoecon. Outcomes Res. 2009; 9: 523-5.
46. Young RP, Hopkins R, Eaton TE,. Pharmacological actions of statins: potential utility in COPD. Eur. Respir. Rev. 2009; 18: 222-32.
47. Mortensen EM, Copeland LA, Pugh MJ, et al,. Impact of statins and ACE inhibitors on mortality after COPD exacerbations. Respir. Res. 2009; 10: 45.
48. Marin L, Colombo P, Bebawy M, et al,. Chronic obstructive pulmonary disease: patho-physiology, current methods of treatment and the potential for simvastatin in disease management. Expert Opin. Drug Deliv. 2011; 8: 1205-20.
49. Di Marco F, Guazzi M, Vicenzi M, et al,. Effect of enalapril on exercise cardiopulmonary performance in chronic obstructive pulmonary disease: a pilot study. Pulm. Pharmacol. Ther. 2010; 23: 159-64.
50. Mancini GBJ, Etminan M, Zhang B, et al,. Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease. J. Am. Coll. Cardiol. 2006; 47: 2554-60.
51. Yusuf S, Wittes J, Friedman L,. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA 1988; 260: 2088-93.
52. Freemantle N, Urdahl H, Eastaugh J, et al,. What is the place of beta-blockade in patients who have experienced a myocardial infarction with preserved left ventricular function? Evidence and (mis)interpretation. Prog. Cardiovasc. Dis. 2002; 44: 243-50.
53. Ozasa N, Kimura T, Morimoto T, et al,. Lack of effect of oral beta-blocker therapy at discharge on long-term clinical outcomes of ST-segment elevation acute myocardial infarction after primary percutaneous coronary intervention. Am. J. Cardiol. 2010; 106: 1225-33.
54. Egred M,. Under-use of beta-blockers in patients with ischaemic heart disease and concomitant chronic obstructive pulmonary disease. QJM 2005; 98: 493-7.
55. Olenchock BA, Fonarow GG, Pan W, et al,. Current use of beta blockers in patients with reactive airway disease who are hospitalized with acute coronary syndromes. Am. J. Cardiol. 2009; 103: 295-300.
56. Salpeter SR, Ormiston TM, Salpeter EE,. Cardioselective beta-blockers in patients with reactive airway disease: a meta-analysis. Ann. Intern. Med. 2002; 137: 715-25.
57. Albouaini K, Andron M, Alahmar A, et al,. Beta-blockers use in patients with chronic obstructive pulmonary disease and concomitant cardiovascular conditions. Int. J. Chron. Obstruct. Pulmon. Dis. 2007; 2: 535-40.
58. Goldberger JJ, Bonow RO, Cuffe M, et al,. β-Blocker use following myocardial infarction: low prevalence of evidence-based dosing. Am. Heart J. 2010; 160: 435-42.
59. Dransfield MT, Rowe SM, Johnson JE, et al,. Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD. Thorax 2008; 63: 301-5.
60. Rutten FH, Zuithoff NP, Hak E, et al,. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch. Intern. Med. 2010; 170: 880-87.
61. Fox K, Ford I, Steg PG, et al,. Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): a randomised, double-blind, placebo-controlled trial. Lancet 2008; 372: 807-16.
62. Fox K, Ford I, Steg PG, et al,. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur. Heart J. 2009; 30: 2337-45.
63. Ceconi C, Freedman SB, Tardif JC, et al,. Effect of heart rate reduction by ivabradine on left ventricular remodeling in the echocardiographic substudy of BEAUTIFUL. Int. J. Cardiol. 2011; 146: 408-14.
64. Calverley PM, Anderson JA, Celli B, et al,. Cardiovascular events in patients with COPD: TORCH study results. Thorax 2010; 65: 719-25.
65. Nishiyama K, Morimoto T, Furukawa Y, et al,. Chronic obstructive pulmonary diseaseâan independent risk factor for long-term cardiac and cardiovascular mortality in patients with ischemic heart disease. Int. J. Cardiol. 2010; 143: 178-83.
66. Selvaraj C, Gurm H, Gupta R, et al,. Chronic obstructive pulmonary disease as a predictor of mortality in patients undergoing percutaneous coronary intervention. Am. J. Cardiol. 2005; 96: 756-9.
67. Campo G, Saia F, Guastaroba P, et al,. Prognostic impact of hospital readmissions after primary percutaneous coronary intervention. Arch. Intern. Med. 2011; 171: 1948-9.
68. Hansell AL, Walk JA, Soriano JB,. What do chronic obstructive pulmonary disease patients die from? A multiple cause coding analysis. Eur. Respir. J. 2003; 22: 809-14.
69. Sidney S, Sorel M, Quesenberry CP, et al,. COPD and incident cardiovascular disease hospitalizations and mortality: Kaiser Permanente Medical Care Program. Chest 2005; 128: 2068-75.
70. McGarvey LP, John M, Anderson JA, et al,. Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee. Thorax 2007; 62: 411-15.
71. Harvey MG, Hancox RJ,. Elevation of cardiac troponins in exacerbation of chronic obstructive pulmonary disease. Emerg. Med. Australas. 2004; 16: 212-15.
72. Brekke PH, Omland T, Holmedal SH, et al,. Troponin T elevation and long-term mortality after chronic obstructive pulmonary disease exacerbation. Eur. Respir. J. 2008; 31: 563-70.
73. Chang CL, Robinson SC, Mills GD, et al,. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax 2011; 66: 764-8.
74. Hoiseth AD, Neukamm A, Karlsson BD, et al,. Elevated high-sensitivity cardiac troponin T is associated with increased mortality after acute exacerbation of chronic obstructive pulmonary disease. Thorax 2011; 66: 775-81.
75. Maclay JD, McAllister DA, Johnston S, et al,. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax 2011; 66: 769-74.
76. National Institute for Health and Clinical Excellence. Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care. National Clinical Guideline Centre. 2010. [Accessed 20 Dec 2011.] Available from URL
77. van Gestel YR, Hoeks SE, Sin DD, et al,. Impact of cardioselective beta-blockers on mortality in patients with chronic obstructive pulmonary disease and atherosclerosis. Am. J. Respir. Crit. Care Med. 2008; 178: 695-700.